Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Is a healthy male or female who is an early or moderate pre-term infant (≥29 to 34 weeks and 6 days gestational age) or a late pre-term or full-term infant (≥35 weeks gestational age)~* For the phase 2b cohort only: Has a chronological age \>2 weeks of age up to 1 year and is entering their first RSV season at the time of obtaining documented informed consent.~* For the phase 3 cohort only: Has a chronological age from birth up to 1 year and is entering their first RSV season at the time of obtaining documented informed consent.~* For participants in South Korea only: Weighs ≥2 kg~Key Exclusion Criteria:~* Is recommended to receive palivizumab per local guidelines or professional society recommendations.~* Has known hypersensitivity to any component of clesrovimab~* Has a bleeding disorder contraindicating IM administration~* Has had a recent illness with rectal temperature ≥100.5°F (≥38.1°C) or axillary temperature ≥100.0°F (≥37.8°C) within 72 hours predose~* Has received any vaccine or monoclonal antibody for the prevention of RSV~* Is currently participating in or has participated in an interventional clinical study with an investigational compound or device at any time before first dose administration or while participating in this study

- Gender: ALL
- Minimum Age: None
- Maximum Age: 1 Year
- Healthy Volunteers: t

Study Arms:
- Clesrovimab (Type: EXPERIMENTAL): Participants receive a single intramuscular (IM) administration of clesrovimab on Day 1.
- Placebo (Type: PLACEBO_COMPARATOR): Participants receive a single IM administration of placebo on Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).